Patient characteristics (n = 25)
| Characteristic . | Status . | No. . | Median . | Range . |
|---|---|---|---|---|
| Sex | ||||
| Male | 18 | |||
| Female | 7 | |||
| Age, y | ||||
| Patient | 62 | 35-77 | ||
| Donor | 38 | 20-69 | ||
| Donor relationship | ||||
| Child | 18 | |||
| Sibling | 7 | |||
| Recipient seropositive CMV status | 16 | |||
| HLA match | ||||
| 5/10 | 22 | |||
| 6/10 | 1 | |||
| 7/10 | 2 | |||
| HCT-CI | ||||
| 0-2 | 8 | |||
| ≥3 | 17 | |||
| Karnofsky performance status <90 | 20 | |||
| Female donor/male recipient | 8 | |||
| Donor KIR haplotype | ||||
| A/A | 7 | |||
| B/X | 18 | |||
| Disease | ||||
| Ph+ acute lymphoblastic leukemia | CR1 | 2 | ||
| Acute myelogenous leukemia-MK | CR1 | 1 | ||
| Acute myelogenous leukemia | CR2 | 1 | ||
| Myelodysplastic syndrome | ||||
| EB2 | 3 | |||
| EB1 | 2 | |||
| RCMD | 2 | |||
| Chronic lymphocytic leukemia | Rel-sens | 2 | ||
| Chronic lymphocytic leukemia | Rel-res | 1 | ||
| Hodgkin lymphoma | Rel-sens | 2 | ||
| MCL | PIF-sens | 1 | ||
| MCL | Rel-sens | 1 | ||
| DLBCL | Rel-sens | 1 | ||
| MM-HR | Rel-sens | 3 | ||
| MM-SR | Rel-sens | 3 | ||
| Disease risk index | ||||
| Low | 4 | |||
| Intermediate | 16 | |||
| High | 5 | |||
| Previous autologous SCT | 9 | |||
| CD34 dose, × 106/kg | 5.01 | 3.23-5.09 | ||
| CD3 dose, × 108/kg | 1.58 | 0.27-5.33 |
| Characteristic . | Status . | No. . | Median . | Range . |
|---|---|---|---|---|
| Sex | ||||
| Male | 18 | |||
| Female | 7 | |||
| Age, y | ||||
| Patient | 62 | 35-77 | ||
| Donor | 38 | 20-69 | ||
| Donor relationship | ||||
| Child | 18 | |||
| Sibling | 7 | |||
| Recipient seropositive CMV status | 16 | |||
| HLA match | ||||
| 5/10 | 22 | |||
| 6/10 | 1 | |||
| 7/10 | 2 | |||
| HCT-CI | ||||
| 0-2 | 8 | |||
| ≥3 | 17 | |||
| Karnofsky performance status <90 | 20 | |||
| Female donor/male recipient | 8 | |||
| Donor KIR haplotype | ||||
| A/A | 7 | |||
| B/X | 18 | |||
| Disease | ||||
| Ph+ acute lymphoblastic leukemia | CR1 | 2 | ||
| Acute myelogenous leukemia-MK | CR1 | 1 | ||
| Acute myelogenous leukemia | CR2 | 1 | ||
| Myelodysplastic syndrome | ||||
| EB2 | 3 | |||
| EB1 | 2 | |||
| RCMD | 2 | |||
| Chronic lymphocytic leukemia | Rel-sens | 2 | ||
| Chronic lymphocytic leukemia | Rel-res | 1 | ||
| Hodgkin lymphoma | Rel-sens | 2 | ||
| MCL | PIF-sens | 1 | ||
| MCL | Rel-sens | 1 | ||
| DLBCL | Rel-sens | 1 | ||
| MM-HR | Rel-sens | 3 | ||
| MM-SR | Rel-sens | 3 | ||
| Disease risk index | ||||
| Low | 4 | |||
| Intermediate | 16 | |||
| High | 5 | |||
| Previous autologous SCT | 9 | |||
| CD34 dose, × 106/kg | 5.01 | 3.23-5.09 | ||
| CD3 dose, × 108/kg | 1.58 | 0.27-5.33 |
CR1, first complete response; CR2, second complete response; DLBCL, diffuse large B-cell lymphoma; EB1, excess blasts-1; EB2, excess blasts-2; HR, high risk; MCL, mantle cell lymphoma; MK, monosomal karyotype; MM, multiple myeloma; Ph+, Philadelphia chromosome positive; PIF, primary inducion failure; RCMD, refractory cytopenia with multilineage dysplasia; rel-res, chemotherapy-resistant relapse; rel-sens, chemotherapy-sensitive relapse; SCT, stem cell transplantation; SR, standard risk.